Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Heartburn Drug Uniform Warnings Advocated By Advisory Panels

This article was originally published in The Tan Sheet

Executive Summary

All OTC heartburn medications should carry stronger warnings alerting consumers about when they may be suffering from a more serious condition, members of FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees recommended

You may also be interested in...



Two GDAC Members Weigh In On Prilosec 1 Without Voting

An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma

Two GDAC Members Weigh In On Prilosec 1 Without Voting

An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma

Two GDAC Members Weigh In On Prilosec 1 Without Voting

An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel